Think Tank Innovations Ltd is a company active in the healthcare domain. The company is interested in expanding their current working system Sharesmart application by benefiting from advanced technology to develop an integrated environment for healthcare solutions in order to better service a wider community locally and globally. Students to be involved in this project will build a data repository to host data to be collected, cleaned, built, integrated and processed for knowledge discovery which will guide more focused decision making.
Xenon has developed isoform selective blockers of the sodium channels that are expressed in CNS neurons with the intent of developing them for therapeutic use, especially epilepsy. The primary goal of this research project is to determine the activity of compounds on CNS neurons. Until now, all characterization has been done with heterologously expressed channels. Until recently, a major impediment to such studies is the heterogenous nature of CNS neurons, so that a large number of studies need to be conducted for a complete characterization.
There are many compression garment products on the market claiming to improve some aspect of performance, however their claims are not validated with empirical data. In fact, current literature regarding the benefits of compression garments on cardiovascular and biomechanical performance is controversial; with many results suggesting non-significant or even negative effects provided by the compression garment.
Clinical experience demonstrates that canine patients commonly suffer from neuropathic pain and little is known to address this issue. Our study aims to investigate different tools for the diagnosis and treatment of neuropathic pain. Forty dogs with naturally-occurring neuropathic pain will be included in a prospective, randomized, masked clinical trial using appropriate inclusion and exclusion criteria.
Treatments that involve activating a patients own immune system, immunotherapies, are becoming important cancer therapies. Unfortunately, doctors dont always know the best way to combine these therapies to best treat patients and the current tools they have to evaluate treatment success dont work well for immunotherapies. Molecular imaging, particularly magnetic resonance imaging (MRI) or positron emission tomography (PET) can help researchers learn more about how these therapies work and how best to combine them.
The prevalence of diabetes is growing rapidly and currently, over 60 million people worldwide use insulin treatment to manage their diabetes. However, insulin treatment can result in hypoglycemia or low blood sugar levels. To date only retroactive treatments are available to treat hypoglycemia, which affects an individuals quality of life and increases the likelihood of recurring bouts of hypoglycemia as well as development of cardiovascular or renal disease.
The aim of the proposed research is to investigate the cellular mechanistic effects of supplementation with a hypocaloric meal replacement product (Optifast-900; Nestlé Canada) containing cysteine and glycine, which are amino acid precursors of the antioxidant glutathione. Impaired cellular glutathione redox normally occurs with aging and metabolic disorders, however, this study will focus on a population in which we have previously observed impaired muscle cellular glutathione redox and slow weight loss during the exclusive dietary consumption of Optifast-900.
University of British Columbia and Amgen British Columbia (ABC) will collaborate to develop a safe and efficient lipid-based vaccine delivery system that can be used in laboratory animals to enhance the production of specific antibodies against difficult targets. These antibodies can be further screened and characterized for treating various diseases in humans.
Aptamer based sensor development can be challenging. While aptamer selection has provided a very useful method of producing molecules that selectively bind compounds of interest to the fields of public health, regulatory control and legal enforcement, the steps required for incorporation of aptamers into sensors are not trivial. Specifically, gaging how well aptamers bind their target and determining how aptamer modification for sensor incorporation may affect their properties have slowed down the commercialization of this technology.
The vision of this proposed project is to design and build a collaborative service robot that will help people with developmental disabilities (DD) reach their personal goals and achieve greater independence, using existing and new technologies. This will allow the industry partner, JDQ, to advance the type of services provided to people with DD and their caregivers in a group home environment, through its partnership with Developmental Disabilities Association (DDA).